Human p16-INK4a-TAT

Slide this table

Cat-Nr.100-422
Size25 µg
Price170 €
SourceE. coli
LabelTAT-Fusionprotein
Formulationlyophilized
Purity Confirmation> 95% by SDS-PAGE & HPLC analyses
Length [aa]167
Molecular Weight18 kDa
Endotoxin Levels< 0.1 ng/µg of protein (<1EU/µg)
Biological ActivityData not available.
Species ReactivityHuman
SynonymsCyclin-dependent kinase inhibitor 2A, Cyclin-dependent kinase 4 inhibitor A, CDK4I, MTS-1, Multiple tumor suppressor 2
Descriptionp16-INK4a is a nuclear protein that regulates the cell cycle by inhibiting cyclin dependent kinase-4 (CDK4) and CDK6. p16-INK4a inhibits CDK activity by binding to the CDK molecules in a manner that interferes with their ability to interact with cyclin D. This activity has the effect of suppressing tumor formation and growth, and of inducing replicative senescence in various normal cells, including stem cells. The expression of p16-INK4a steadily increases with age and tends to accumulate in stem cell compartments. The deletion, rearrangement, or mutation of the p16-INK4a gene is frequently found in melanomas as well as in certain other types of cancer. P16-INK4a and other transcription factors have been introduced into cells by DNA transfection, viral infection, or microinjection. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors and other nuclear proteins into primary as well as transformed cells. Recombinant human p16-INK4a-TAT expressed in E. coli is a 18 kDa protein containing 167 amino-acid residues, including the 156 residues of full-length p16-INK4a and a 12-residue C-terminal TAT peptide (GYGRKKRRQRRR).
Protein SequenceEPAAGSSMEP SADWLATAAA RGRVEEVRAL LEAGALPNAP NSYGRRPIQV MMMGSARVAE LLLLHGAEPN CADPATLTRP VHDAAREGFL DTLVVLHRAG ARLDVRDAWG RLPVDLAEEL GHRDVARYLR AAAGGTRGSN HARIDAAEGP SDIPDGYGRK KRRQRRR
Uniprot IDP42771
Protein RefSeqNP_478104.2
mRNA RefSeqNM_058197.4

All prices plus VAT + possible delivery charges